Get the Stockscreener App
1.90
3.83%
0.07
After Hours:
1.91
0.01
+0.53%
Jasper Therapeutics Inc stock is traded at $1.90, with a volume of 310.53K.
It is up +3.83% in the last 24 hours and up +11.11% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
See More
Previous Close:
$1.83
Open:
$1.83
24h Volume:
310.53K
Relative Volume:
0.21
Market Cap:
$53.17M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-0.3072
EPS:
-6.1852
Net Cash Flow:
$-52.33M
1W Performance:
+6.15%
1M Performance:
+11.11%
6M Performance:
-71.94%
1Y Performance:
-90.90%
1-Day Range:
$1.83
$1.92
1-Week Range:
$1.76
$1.92
52-Week Range:
$1.39
$21.27
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
1.90 | 51.21M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-07-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-13-25 | Initiated | UBS | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-08-24 | Initiated | BTIG Research | Buy |
| Jun-27-24 | Initiated | Stifel | Buy |
| May-06-24 | Initiated | H.C. Wainwright | Buy |
| Apr-03-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-18-24 | Initiated | TD Cowen | Outperform |
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
What analysts say about Jasper Therapeutics Inc stockTop Performing Stocks & Low Risk Trading Alerts - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
2025-12-28 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out | NDAQ:JSPR | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Earnings Notes - Trefis
Jasper Therapeutics (JSPR) Price Target Decreased by 15.25% to 13.09 - MSN
Evercore ISI Remains a Buy on Jasper Therapeutics (JSPR) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect - ACCESS Newswire
2025-12-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect | NDAQ:JSPR | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Jasper Therapeutics (NASDAQ:JSPR) Stock Price Down 7.3% – Time to Sell? - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Connect - ACCESS Newswire
Penny Stocks To Watch NowDecember 2nd - MarketBeat
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Jasper’s Stock Is In The Basement, But The Bet Is Binary - Finimize
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma DataSlideshow (NASDAQ:JSPR) 2025-12-04 - Seeking Alpha
Jasper Therapeutics Reports Positive Phase 1b Study Results - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR) - The Globe and Mail
Jasper Therapeutics stock maintains Market Outperform rating at Citizens By Investing.com - Investing.com Canada
Jasper Therapeutics’ Briquilimab Program Shines Amid Financial Losses - StocksToTrade
Jasper Therapeutics, Inc. (JSPR) Stock: Surges as New Asthma Trial Data Shows Promising Results - parameter.io
Jasper Therapeutics’ Briquilimab: Stepping Up? - StocksToTrade
Can Jasper Therapeutics Deliver on New Studies? - timothysykes.com
$1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Anticipates Growth with Briquilimab Highlights - timothysykes.com
Why Is Jasper Therapeutics Stock Surging Tuesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Can Jasper Therapeutics’ Progress Propel Its Stock? - timothysykes.com
JSPR Explodes on Briquilimab Asthma Breakthrough - RagingBull
Jasper stock jumps after positive asthma study results - Investing.com India
Jasper Therapeutics Reports Positive Results For Briquilimab In Allergic Asthma Phase 1b Study - Nasdaq
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation - Sahm
Jasper Therapeutics Reports Positive Data from ETESIAN Study and BEACON Investigation - TradingView
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in ... - Enidnews.com
Jasper Stock Jumps After Promising New Asthma Study Results - Sahm
Jasper Therapeutics To Host Webinar To Present BEACON And ETESIAN Study Results - Nasdaq
Jasper Therapeutics to Host an Investor Webinar on December - GlobeNewswire
Jasper Therapeutics (Nasdaq: JSPR) to host Dec. 2 webinar on ETESIAN, BEACON studies - Stock Titan
JSPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ROSEN, REGARDED INVESTOR COUNSEL, Encourages Jasper Therapeutics - The National Law Review
Jasper Therapeutics Inc. (JSPR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Hold” by Brokerages - Defense World
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):